AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request</u>. All other information may be filled in by office staff; fax to <u>1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization may be delayed.</u>

<u>Drug Requested</u> : (select <u>ONE</u> of the following)	
□ Grastek® (Timothy Grass Pollen Extract)	□ Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract)
MEMBER & BRECCHIPER INFORMA	TION
MEMBER & PRESCRIBER INFORMA	TION: Authorization may be delayed if incomplete.
Member Name:	
Member AvMed #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	
DEA OR NPI #:	
DRUG INFORMATION: Authorization ma	
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code:
Weight:	Date:
Recommended Dosage: Dissolve one tablet un	nder the tongue daily for 3 consecutive years

- Grass pollen season = Mid May to July; the duration of authorization will be for a 12-month period and will remain active for 3 consecutive years
- Only 1 <u>grass allergen-specific immunotherapy</u> product can be approved for use at a time (i.e., Oralair®, Grastek® or SQ allergy shots)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Length of Authorization: 3 years

☐ Medication is prescribed by or in consultation with an allergist or immunologist

	Member must meet ONE of the following age requirements:
	☐ For Grastek requests: Member must be between the ages of 5 and 65 years old
	☐ For Oralair requests: Member must be between the ages of 10 and 65 years old
	Member must meet ONE of the following treatment initiation requirements:
	□ For Grastek requests: Treatment will be initiated at least 12 weeks before the expected onset of each grass pollen season and will be continued throughout the grass pollen season
	□ For Oralair requests: Treatment will be initiated at least 16 weeks before the expected onset of each grass pollen season and will be continued throughout the grass pollen season
	Member has a diagnosis of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by <u>ONE</u> of the following [skin test or in vitro testing for pollen-specific IgE antibodies results to any of the following five grass species (i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass meadow fescue, or Redtop) <u>must</u> be submitted with request]:
	□ Positive skin prick test for at least one grass pollen contained in requested medication
	Positive in vitro testing for pollen-specific IgE antibodies for at least one grass pollen contained in requested medication
	Member has had trial and inadequate symptom control with at least <u>TWO</u> of the following within the past 12 months (verified by chart notes or pharmacy paid claims):
	☐ Intranasal corticosteroid (e.g., fluticasone, budesonide, triamcinolone)
	☐ Intranasal antihistamine (e.g., azelastine, olopatadine)
	☐ Oral antihistamine (e.g., levocetirizine)
	☐ Leukotriene inhibitor (e.g., montelukast, zafirlukast)
	Provider has prescribed auto-injectable epinephrine (verified by chart notes or pharmacy paid claims)
	Provider attests that member does NOT have any of the following:
	• Receiving concomitant therapy with other allergen immunotherapy products (review claims for documenting concurrent use of Oralair, Grastek)
	• History of severe, unstable or uncontrolled asthma: (review claims documenting Xolair + med/high dose of an inhaled corticosteroid/Long-acting beta agonist on file)
	History of severe systemic allergic reaction (review claims documenting Hereditary Angioedema

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *

(HAE) medications)

History of eosinophilic esophagitis

^{*}Approved by Pharmacy and Therapeutics Committee: 2/16/2023 REVISED/UPDATED: 03/09/2023